secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0000950170-24-103097
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Pharma appoints Fred Hassan to board; directors Guyer, Adamis resign for Merck roles
--------------------------------------------------------------------------------

- David Guyer and Anthony Adamis resigned from board effective Sept 3, 2024 due to full-time roles at Merck & Co.
- Fred Hassan appointed to board; board size reduced from 9 to 8 members.
- Hassan received option grant for 60,000 shares vesting over 3 years, annual cash retainer $45k.
- Karen Zaderej and Stuart Duty join Compensation Committee (Zaderej as Chair); Hassan joins Governance Committee.
- Company nearing first patient dosing in Phase 3 LUGANO trial of DURAVYU for wet AMD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/0000950170-24-103097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/eypt-20240903.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-103097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer